Nuo Therapeutics Inc represents a values-driven corporate philosophy focused on advancing advanced wound care solutions. The company is committed to improving patient outcomes through innovation, research, and development. Nuo Therapeutics Inc places a strong emphasis on integrity, delivering high-quality products, and fostering collaborations with healthcare professionals. By prioritizing patient needs, the company strives to provide effective therapies that enhance healing processes. Nuo Therapeutics Inc's dedication to excellence and its patient-centered approach make it a leading player in the field of advanced wound care.

Nuo Therapeutics Inc is primarily present in the United States of America.

Nuo Therapeutics Inc has achieved significant milestones in its journey. The company successfully developed and gained FDA approval for the Aurix System, a groundbreaking autologous wound treatment technology. It has also established a robust distribution network, expanding its reach and ensuring widespread availability of its products. Nuo Therapeutics Inc has consistently demonstrated a commitment to innovation and research, making advancements in regenerative medicine. The company's strong financial performance and strategic partnerships have further solidified its position in the healthcare industry. This has enabled Nuo Therapeutics Inc to make a positive impact on patient care and position itself as a leading player in the field.

Nuo Therapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative products for the treatment of chronic wound care. Founded in 2009, Nuo Therapeutics specializes in biodefense, regenerative medicine, and bioelectric medicine. The company focuses on utilizing its patented platform technology, Aurix, to provide advanced wound care solutions. Nuo Therapeutics aims to enhance the healing process and improve patient outcomes through the application of bioelectric stimulation. With a strong commitment to research and development, Nuo Therapeutics continues to make advancements in the field of wound care, ensuring optimal treatment options for patients worldwide.

The main competitors of Nuo Therapeutics Inc in the market include companies such as Acelity, Smith & Nephew, and Molnlycke Health Care.

Nuo Therapeutics Inc is primarily active in the healthcare and biotechnology industries.

Nuo Therapeutics Inc is a biomedical company that focuses on developing and commercializing innovative products for the management of chronic wounds. Their business model revolves around providing advanced therapies for patients with chronic ulcers, such as their flagship product Aurix. Nuo Therapeutics Inc aims to improve healthcare outcomes by offering autologous therapies that utilize a patient's own platelet and plasma components. With a focus on regenerative medicine, Nuo Therapeutics Inc strives to address the unmet needs of patients suffering from non-healing wounds, offering novel treatment options that can potentially accelerate the healing process.

Το Ρ/Ε δεν μπορεί να υπολογιστεί αυτή τη στιγμή για το Nuo Therapeutics.

Το KUV δεν μπορεί να υπολογιστεί αυτή τη στιγμή για Nuo Therapeutics.

Το AlleAktien Qualitätsscore για το Nuo Therapeutics είναι 3/10.

Τα έσοδα δεν μπορούν να υπολογιστούν επί του παρόντος για Nuo Therapeutics.

Τα κέρδη για τον Nuo Therapeutics δεν μπορούν να υπολογιστούν αυτή τη στιγμή.

Nuo Therapeutics Inc is a pharmaceutical company focused on the development and marketing of novel biological products for patients suffering from various chronic wounds, such as diabetic foot ulcers. The company has two divisions: the wound care division and the neurological regeneration division. The wound care division offers the unique Autologous Wound Matrix (AWM®) System, which is made from the patient's own blood. The AWM® System promotes healing of chronic wounds in patients by forming a matrix that supports the growth of new cells and tissues. This system is used in patients with chronic wounds who do not respond to other treatment methods or have delayed wound healing. The neurological regeneration division offers the Neuropathological Sibling System (NGS®), which is designed to restore the cognitive abilities of stroke patients. The NGS® System supports patient rehabilitation through the use of innovative medical devices specifically developed to increase blood circulation and stimulate the brain. Nuo Therapeutics aims to revolutionize the care of patients with chronic wounds and stroke patients by offering industry-leading biological products and advanced technologies. Nuo Therapeutics' business model is based on an innovative approach, working closely with physicians, hospitals, and insurance companies to optimize patient care. The company focuses on marketing products based on sound research and development that have been approved by the US Food and Drug Administration (FDA). Nuo Therapeutics relies on a highly qualified team of scientists, engineers, and physicians actively involved in the research and development of new products and technologies. These teams collaborate closely with renowned universities, research institutions, and hospitals to optimize the effectiveness and safety of their products. Nuo Therapeutics is working on expanding its business through the development of new therapies to improve outcomes for patients with chronic wounds and stroke patients. The company also plans to expand its presence internationally to enhance access to its products in international markets. Overall, Nuo Therapeutics is a leading company in wound care and neuroregeneration. The company is committed to providing its patients with high-quality treatment options by introducing innovative products and technologies to the market. With a dedicated team of innovative thinkers and researchers, Nuo Therapeutics will continue to revolutionize the care of patients with chronic wounds and stroke patients in the future.

Η Nuo Therapeutics καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Nuo Therapeutics αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Nuo Therapeutics είναι US67059V2097.

Το WKN της Nuo Therapeutics είναι A2AP5P.

Ο τίκερ της Nuo Therapeutics είναι AURX.

Κατά τους τελευταίους 12 μήνες η Nuo Therapeutics κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Nuo Therapeutics προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Nuo Therapeutics ανέρχεται σήμερα στο .

Nuo Therapeutics πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Nuo Therapeutics πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Nuo Therapeutics ανατίθεται στον τομέα '—'.

Για να λάβεις το τελευταίο μέρισμα των Nuo Therapeutics από την 4/3/2025 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 4/3/2025.

Η τελευταία μερίσματος έγινε στις 4/3/2025.

Το έτος 2024, η Nuo Therapeutics διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Nuo Therapeutics καταβάλλονται σε USD.